K

Kura Oncology
D

KURA

8.26500
USD
0.12
(1.41%)
Market Closed
Volume
22,247
EPS
-2
Div Yield
-
P/E
-4
Market Cap
642,717,394
Related Instruments
    C
    COLM
    0.461
    (0.51%)
    90.741 USD
    LULU
    LULU
    -6.76
    (-1.85%)
    358.91 USD
    NKE
    NKE
    -0.750
    (-0.97%)
    76.500 USD
    P
    PVH
    0.040
    (0.05%)
    78.710 USD
    R
    RL
    -8.88
    (-3.10%)
    277.69 USD
    U
    UAA
    -0.06000
    (-0.84%)
    7.09500 USD
    U
    ULTA
    -5.19
    (-1.42%)
    361.54 USD
    V
    VFC
    -0.970
    (-3.66%)
    25.505 USD
    More
News

Title: Kura Oncology

Sector: Healthcare
Industry: Biotechnology
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operationof the group is carried through the United States.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.